Last Updated: November 16, 2026

Details for Patent: 10,689,377

« Back to Dashboard


Which drugs does patent 10,689,377 protect, and when does it expire?

Patent 10,689,377 protects KRAZATI and is included in one NDA.

This patent has fifty patent family members in thirty-five countries.

Summary for Patent: 10,689,377
Title:KRas G12C inhibitors
Abstract:The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.
Inventor(s):James F. Blake, Laurence E. Burgess, Mark Joseph Chicarelli, James Gail Christensen, Adam Cook, Jay Bradford Fell, John P. Fischer, Matthew Arnold Marx, Macedonio J. Mejia, Pavel Savechenkov, Guy P. A. Vigers, Christopher Ronald Smith, Martha E. Rodriguez
Assignee: Array Biopharma Inc , Mirati Therapeutics Inc
Application Number:US16/191,190
Patent Claim Types:
see list of patent claims
Use; Composition;

Recent additions to Drugs Protected by US Patent 10,689,377

These patents are from the daily update and have not yet been integrated into the regular database
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Product Substance Delist Req. Patent Expiration Usecode Patented / Exclusive Use
Bristol KRAZATI adagrasib TABLET 216340 Dec 12, 2022 RX Yes ⤷  Start Trial Y Y ⤷  Start Trial U-3490 TREATMENT OF ADULT PATIENTS WITH KRAS G12C-MUTATED LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC), AS DETERMINED BY AN FDA APPROVED TEST, WHO HAVE RECEIVED AT LEAST ONE PRIOR SYSTEMIC THERAPY
Bristol KRAZATI adagrasib TABLET 216340 Dec 12, 2022 RX Yes ⤷  Start Trial Y Y ⤷  Start Trial U-3953 TREATMENT, IN COMBINATION WITH CETUXIMAB, OF ADULT PATIENTS WITH KRAS G12C-MUTED LOCALLY ADVANCED OR METASTATIC COLORECTAL CANCER, PER FDA APPROVED TEST, WHERE PRIOR TREATMENT WITH FLUOROPYRIMIDINE-, OXALIPLATIN-, AND IRINOTECAN-BASED CHEMOTHERAPY
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Type >RLD >Patent No. >Product >Substance >Delist Req. >Patent Expiration >Usecode >Patented / Exclusive Use

Drugs Protected by US Patent 10,689,377

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Bristol KRAZATI adagrasib TABLET;ORAL 216340-001 Dec 12, 2022 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y Y TREATMENT OF ADULT PATIENTS WITH KRAS G12C-MUTATED LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC), AS DETERMINED BY AN FDA APPROVED TEST, WHO HAVE RECEIVED AT LEAST ONE PRIOR SYSTEMIC THERAPY ⤷  Start Trial
Bristol KRAZATI adagrasib TABLET;ORAL 216340-001 Dec 12, 2022 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y Y TREATMENT, IN COMBINATION WITH CETUXIMAB, OF ADULT PATIENTS WITH KRAS G12C-MUTED LOCALLY ADVANCED OR METASTATIC COLORECTAL CANCER, PER FDA APPROVED TEST, WHERE PRIOR TREATMENT WITH FLUOROPYRIMIDINE-, OXALIPLATIN-, AND IRINOTECAN-BASED CHEMOTHERAPY ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 10,689,377

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 3710439 ⤷  Start Trial 301279 Netherlands ⤷  Start Trial
European Patent Office 3710439 ⤷  Start Trial CA 2024 00024 Denmark ⤷  Start Trial
European Patent Office 3710439 ⤷  Start Trial PA2024517 Lithuania ⤷  Start Trial
European Patent Office 3710439 ⤷  Start Trial LUC00350 Luxembourg ⤷  Start Trial
European Patent Office 3710439 ⤷  Start Trial 2024C/525 Belgium ⤷  Start Trial
European Patent Office 3710439 ⤷  Start Trial 122024000035 Germany ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.